Literature DB >> 25116322

Oral human papillomavirus infection in men might contribute to HPV serology.

S Syrjänen1, T Waterboer, K Kero, J Rautava, K Syrjänen, S Grenman, M Pawlita.   

Abstract

The prospective Finnish Family HPV Study evaluated the dynamics of human papillomavirus (HPV) infection within families. Here, we focused on HPV serology in men. Seroprevalence at baseline, seroconversion and decay of low-risk (LR)-HPV6 and 11, and high risk (HR)-HPV16, 18 and 45 L1 antibodies in 122 men at 12, 24 and 36 months were determined using Luminex-based multiplex HPV serology, and correlated with demographic data. At baseline, seropositivity to HPV6, 11, 16, 18 and 45 was observed in 41.0, 11.5, 23.0, 13.9 and 5.7 % of the men, respectively. In univariate analysis, LR-HPV seropositivity was related to smoking status, history of genital warts and being seropositive to HR-HPV. Oral HR-HPV DNA and baseline LR-HPV seropositivity predicted HR-HPV seropositivity. Seroconversion to HPV6, 11, 16, 18 and 45 antigens during follow-up was found in 24.6, 11.5, 5.7, 5.7 and 0.8 %, respectively. Seroconversion to LR-HPV was negatively related to a higher number of children and oral sex, and positively associated with seroconversion to HR-HPV. In multivariate analysis, the same predictors remained significant except for the number of children. In univariate generalised estimating equations (GEE) for HR-HPV, being seroconverted to LR-HPV was the only predictor, but lost its significance in multivariate analyses. Decay of all HPV L1 antibodies was rare and observed in 0-2 %. The HPV antibody profile in men was dominated by response to HPV6, also showing the highest cumulative seroconversion. Oral HPV infection might affect HPV serology: (1) HPV DNA in oral mucosa is associated with baseline HR-HPV seropositivity and (2) practising oral sex significantly reduces longitudinal seroconversion to HPV6 and/or 11.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25116322     DOI: 10.1007/s10096-014-2223-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  40 in total

1.  HPV 16 antibody prevalence in Jamaica and the United States reflects differences in cervical cancer rates.

Authors:  H D Strickler; G D Kirk; J P Figueroa; E Ward; A R Braithwaite; C Escoffery; J Drummond; B Goebel; D Waters; R McClimens; A Manns
Journal:  Int J Cancer       Date:  1999-01-29       Impact factor: 7.396

Review 2.  Prevalence of HPV infection among men: A systematic review of the literature.

Authors:  Eileen F Dunne; Carrie M Nielson; Katherine M Stone; Lauri E Markowitz; Anna R Giuliano
Journal:  J Infect Dis       Date:  2006-09-12       Impact factor: 5.226

3.  Transmission of high-risk human papillomavirus (HPV) between parents and infant: a prospective study of HPV in families in Finland.

Authors:  Marjut A M Rintala; Seija E Grénman; Mirja H Puranen; Erika Isolauri; Ulla Ekblad; Pentti O Kero; Stina M Syrjänen
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

Review 4.  The epidemiology of genital human papillomavirus infection.

Authors:  Helen Trottier; Eduardo L Franco
Journal:  Vaccine       Date:  2006-03-30       Impact factor: 3.641

5.  Antibodies against human papillomavirus type 6 capsids are elevated in men with previous condylomas.

Authors:  A Wikström; C Eklund; G von Krogh; P Lidbrink; J Dillner
Journal:  APMIS       Date:  1997-11       Impact factor: 3.205

6.  Seroreactivity to human papillomavirus type 16 virus-like particles is lower in high-risk men than in high-risk women.

Authors:  E I Svare; S K Kjaer; B Nonnenmacher; A M Worm; H Moi; R B Christensen; A J van den Brule; J M Walboomers; C J Meijer; N L Hubbert; D R Lowy; J T Schiller
Journal:  J Infect Dis       Date:  1997-10       Impact factor: 5.226

7.  Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites.

Authors:  J J Carter; M M Madeleine; K Shera; S M Schwartz; K L Cushing-Haugen; G C Wipf; P Porter; J R Daling; J K McDougall; D A Galloway
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

8.  Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students.

Authors:  Jeffrey M Partridge; James P Hughes; Qinghua Feng; Rachel L Winer; Bethany A Weaver; Long-Fu Xi; Michael E Stern; Shu-Kuang Lee; Sandra F O'Reilly; Stephen E Hawes; Nancy B Kiviat; Laura A Koutsky
Journal:  J Infect Dis       Date:  2007-09-13       Impact factor: 5.226

9.  Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men.

Authors:  Anna R Giuliano; Beibei Lu; Carrie M Nielson; Roberto Flores; Mary R Papenfuss; Ji-Hyun Lee; Martha Abrahamsen; Robin B Harris
Journal:  J Infect Dis       Date:  2008-09-15       Impact factor: 5.226

10.  Human papillomavirus prevalence and type distribution in male anogenital sites and semen.

Authors:  Carrie M Nielson; Roberto Flores; Robin B Harris; Martha Abrahamsen; Mary R Papenfuss; Eileen F Dunne; Lauri E Markowitz; Anna R Giuliano
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-06       Impact factor: 4.254

View more
  5 in total

1.  Seroprevalence and Associated Factors of 9-Valent Human Papillomavirus (HPV) Types among Men in the Multinational HIM Study.

Authors:  Shams Rahman; Christine M Pierce Campbell; Dana E Rollison; Wei Wang; Tim Waterboer; Angelika Michel; Michael Pawlita; Luisa L Villa; Eduardo Lazcano Ponce; Amy R Borenstein; Anna R Giuliano
Journal:  PLoS One       Date:  2016-11-30       Impact factor: 3.240

Review 2.  Oral manifestations of human papillomavirus infections.

Authors:  Stina Syrjänen
Journal:  Eur J Oral Sci       Date:  2018-10       Impact factor: 2.612

Review 3.  HNSCC: Tumour Antigens and Their Targeting by Immunotherapy.

Authors:  Adrian von Witzleben; Chuan Wang; Simon Laban; Natalia Savelyeva; Christian H Ottensmeier
Journal:  Cells       Date:  2020-09-15       Impact factor: 6.600

4.  Herpes Simplex Virus Seroprevalence among Pregnant Finnish Women and Their Spouses-A Six-Year Follow-Up Cohort Study.

Authors:  Johanna Laakso; Tytti Vuorinen; Jaana Rautava; Katja Kero; Stina Syrjänen; Veijo Hukkanen
Journal:  Microorganisms       Date:  2022-07-26

5.  Interferon-γ and IL-5 associated cell-mediated immune responses to HPV16 E2 and E6 distinguish between persistent oral HPV16 infections and noninfected mucosa.

Authors:  Anna Paaso; Hanna-Mari Koskimaa; Marij J P Welters; Katja Kero; Jaana Rautava; Kari Syrjänen; Sjoerd H van der Burg; Stina Syrjänen
Journal:  Clin Exp Dent Res       Date:  2021-01-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.